Progenity Stock

progenity.comHealthcareFunding to Date: $177.5MM

Progenity is a provider of highly-complex molecular diagnostic testing allowing healthcare providers to access the most advanced genomic technology to guide patient care at critical life stages.

Register for Details

For more details on financing and valuation for Progenity, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Progenity.

Register Today


Management Team

Eric d'Esparbes
Chief Financial Officer
Sami Shihabi
Chief Commercial Officer
Jared Kearns
Chief Information Officer
Allan Bombard MD
Chief Medical Officer
Harry Stylli Ph.D
Chairman and Chief Executive Officer
Matthew Cooper Ph.D
Chief Scientific Officer

Board Members

Harry Stylli Ph.D
John Bigalke
Samuel Nussbaum MD
Brian Kotzin
Jeffrey Alter
Lynne Powell
Howard Slutsky
Jeffrey Ferrell
Athyrium Capital Management

Other companies like Progenity in the Healthcare sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation


Progenity stock has been up nearly 58% in the past five trading days and more than 170% since early October. As PROG keeps marching higher, is it too late for investors to jump in now?
Progenity sought a declaratory judgment from a California court last year that its Innatal NIPT test didn't infringe six patents held by Natera.
LOS ANGELES, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 27, 2020 deadline to...